Eculizumab

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) were trading higher by more than 5 percent early Tuesday morning after the U.S. Food and Drug Administration approved its therapy called Soliris (eculizumab) for the treatment of adults with generalized myasthenia gravis (gMG). GMG represents a...